- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00297011
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
Valacyclovir+Temovate Gel for the Episodic Treatment of Herpes Labialis: A Patient-Initiated Double-Blind, Placebo-Controlled Study, Randomized Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Herpes simplex labialis is a common, worldwide affliction for which neither public health procedures, vaccines, nor antiviral chemotherapy have had a major impact. The present study has been proposed because it has become clear there are marked limitations to the benefit of antiviral therapy in herpes labialis. Recently, a pilot trial of the combination of famciclovir and topical 0.05% fluocinonide vs famciclovir alone showed that the addition of corticosteroids to the antiviral drug treatment caused a marked and statistically significant reduction in lesion size and a trend to more aborted lesions.
This study is designed as a randomized, placebo-controlled, , patient-initiated study. The objective of this study is to evaluate the safety and efficacy of oral valacyclovir 2grams BID for one day and topical temovate 0.05% gel BID for three days compared to placebo capsules and placebo gel in the episodic treatment of a single episode of recurrent herpes labialis in immunologically normal patients.
Subjects will be screened, randomized to study drug and instructed to start using study drug within one hour of the first sign or symptom of their next episode of herpes labialis. Data on the treated lesion will be collected by clinic visits and a patient diary card.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older.
- A history typical for recurrent herpes labialis. The subject must have experienced three or more cold sores in the last 12 months.
- In general good health, without other serious medical conditions, as determined by the patient's account of his/her medical history.
- Signature on the informed consent document.
Exclusion Criteria:
- Patients who have participated in an investigational drug study in the four-week period prior to enrollment.
- Previous herpes vaccine at any time.
- Patients with major medical conditions such as chronic heart, pulmonary, renal or hepatic diseases.
- Patients with immunodeficiency disorders such as HIV infection or cancer chemotherapy.
- Patients using topical steroids on or near the face or systemic steroids within 30 days of enrollment.
- Women who are pregnant, lactating or breast feeding.
- Women of childbearing potential not using adequate contraception as judged by the Investigator.
- Recent history of alcohol or drug abuse, which in the opinion of the investigator, may interfere with that study patient's compliance with study requirements.
- Significant skin disease such as atopic dermatitis, acne, or rosacea that would interfere with the assessment of lesions.
- Allergy or hypersensitivity to steroids, acyclovir, penciclovir and/or other nucleoside analogues.
- Subjects with impaired renal function as defined as a serum creatinine above the upper limits of normal.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary efficacy variable is the maximum size of the primary lesion complex
|
Secondary Outcome Measures
Outcome Measure |
---|
Secondary variables include: the proportion of primary lesions that are aborted; the mean time to healing of the primary lesion complex the frequency and mean duration of lesion pain among primary lesions; the frequency of secondary lesions
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christopher Hull, MD, University of Utah
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Stomatognathic Diseases
- Mouth Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Herpesviridae Infections
- Lip Diseases
- Herpes Simplex
- Herpes Labialis
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Valacyclovir
- Clobetasol
Other Study ID Numbers
- 50301066
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes Labialis
-
BayerActive, not recruitingRecurrent Herpes LabialisUnited States
-
Topical RemedyBenu BioPharma, LLCCompletedRecurrent Herpes LabialisUnited States
-
NanoBio CorporationCompletedRecurrent Herpes LabialisUnited States
-
Southern California University of Health SciencesCompletedHerpes SimplexUnited States
-
Leciel BonoRecruitingHSV-1 | Herpes Simplex Labialis | Virus | Herpes Simplex 1United States
-
Topical RemedyBenu BioPharma, LLC; Accelovance; Optimal ResearchCompletedRecurrent Herpes LabialisUnited States
-
University of ZurichDevirex AGCompleted
-
NovartisCompleted
-
Hadassah Medical OrganizationUnknownReccurent Herpes Labialis
-
Laboratoire Boreaderme Inc.Ecogene 21Unknown
Clinical Trials on valacyclovir+clobetasol gel
-
LEO PharmaCompletedConnective Tissue Diseases | Skin Tissue DiseasesGermany
-
University of CataniaCompleted
-
University of Nove de JulhoUnknown
-
Malmö UniversitySkane University HospitalRecruitingOral Lichen PlanusSweden
-
Mahidol UniversityCompleted
-
Candel Therapeutics, Inc.Active, not recruitingProstate CancerUnited States, Puerto Rico
-
Radboud University Medical CenterCompletedBioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir (VALID-I)Varicella Zoster Virus Infection | Herpes Simplex Virus InfectionNetherlands
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
GlaxoSmithKlineCompletedHerpes LabialisUnited States